Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MDVN

(MDVN) (MDVN) Stock Price, News & Analysis

(MDVN) logo

About (MDVN) Stock (NASDAQ:MDVN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$81.44
$81.44
50-Day Range
N/A
52-Week Range
$26.41
$81.48
Volume
N/A
Average Volume
3.55 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Remove Ads
Receive MDVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter.

MDVN Stock News Headlines

Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
Notable ETF Outflow Detected - HYLB
See More Headlines

MDVN Stock Analysis - Frequently Asked Questions

(MDVN) (NASDAQ:MDVN) posted its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The company's revenue was up 17.4% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX) and (KITE) (KITE).

Company Calendar

Last Earnings
8/09/2016
Today
3/25/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDVN
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:MDVN) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners